Concepedia

Jennifer L. Brooks

JL

19

Publications

1.4K

Citations

16

H-Index

1995

Active since

Affiliations

Biota Pharmaceuticals (United States)(Current)

University at Albany, State University of New York

Albany State University

Scripps Research Institute

Jennifer L. Brooks is an author at Biota Pharmaceuticals (United States) specializing in medicine, biochemistry, and drug discovery.

Top concepts

Publications per year

1995–2021

19

Publications

19

Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P <sub>1</sub> ) and receptor‐5 (S1P <sub>5</sub> ) agonist with autoimmune disease‐modifying activity

Fiona L. Scott, Bryan Clemons, Jennifer L. Brooks et al. · British Journal of Pharmacology · 2016 · 296 citations · Full text

Structure−Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase

Anne B. Eldrup, Charles Allerson, C. Frank Bennett et al. · Journal of Medicinal Chemistry · 2004 · 187 citations · Full text

, , +15

Structure−Activity Relationship of Heterobase-Modified 2‘-<i>C</i>-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication

Anne B. Eldrup, Marija Prhavc, Jennifer L. Brooks et al. · Journal of Medicinal Chemistry · 2004 · 185 citations

The Pleckstrin Homology Domain in Insulin Receptor Substrate-1 Sensitizes Insulin Signaling

Martin G. Myers, Timothy C. Grammer, Jennifer L. Brooks et al. · Journal of Biological Chemistry · 1995 · 115 citations · Full text

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Robert Peach et al. · The Journal of Clinical Pharmacology · 2017 · 106 citations · Full text

Rows per page

1–5 of 19